Abiopharma

IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, andTrodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer